Evidence map›Paper›PMID 33533128›Full record

ArticleJournal of neuroscience research2021

Ethanol modulation of cerebellar neuroinflammation in a postnatal mouse model of fetal alcohol spectrum disorders.

Cynthia J M Kane, James C Douglas, Tonya Rafferty, Jennifer W Johnson, Victoria M Niedzwiedz-Massey, Kevin D Phelan, Ania Katarzyna Majewska, Paul D Drew

Open access · greenAbstract read
In one paragraph

Article in Journal of neuroscience research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Alcohol Toxicity in the Developing Cerebellum.Diagnostics (Basel, Switzerland) · 2024
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Cynthia J M KaneDepartment of Neurobiology and Developmental Sciences, Biomedical Research Center II, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
James C DouglasDepartment of Neurobiology and Developmental Sciences, Biomedical Research Center II, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Tonya RaffertyDepartment of Neurobiology and Developmental Sciences, Biomedical Research Center II, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Jennifer W JohnsonDepartment of Neurobiology and Developmental Sciences, Biomedical Research Center II, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Victoria M Niedzwiedz-MasseyDepartment of Neurobiology and Developmental Sciences, Biomedical Research Center II, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Kevin D PhelanDepartment of Neurobiology and Developmental Sciences, Biomedical Research Center II, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Ania Katarzyna MajewskaDepartment of Neuroscience, Center for Visual Science, University of Rochester, Rochester, NY, USA.ORCID 0000-0002-2167-6849
Paul D DrewDepartment of Neurobiology and Developmental Sciences, Biomedical Research Center II, University of Arkansas for Medical Sciences, Little Rock, AR, USA.ORCID 0000-0001-8984-8099
University of Arkansas for Medical Sciences · USUniversity of Rochester · US

Funding

VISUAL INDICES OF NEUROTOXICITYP30ES001247 · NIEHS · UNIVERSITY OF ROCHESTER · PI Sally W Thurston · 1985 to 2026
$42.8M
Dynamic neuroimmune interactions in the onset and progression of FASDR01AA027111 · NIAAA · UNIV OF ARKANSAS FOR MED SCIS · PI DREW, PAUL D, MAJEWSKA, ANNA K · 2018 to 2022
$2.3M
Neuroinflammation: Role in FASD Cognitive DeficitsR01AA026665 · NIAAA · UNIV OF ARKANSAS FOR MED SCIS · PI DREW, PAUL D, HAMILTON, DEREK A. · 2018 to 2022
$1.9M
Regulation of Neuroimmune Responses in FASD ModelsR01AA024695 · NIAAA · UNIV OF ARKANSAS FOR MED SCIS · PI DREW, PAUL D, KANE, CYNTHIA J. · 2016 to 2020
$1.7M
NIAAA NIH HHS R01 AA024695NIAAA NIH HHS R01 AA026665NIAAA NIH HHS R01 AA027111NIEHS NIH HHS P30 ES001247
6 · The paper itself

Abstract

Fetal alcohol spectrum disorders (FASD) are alarmingly common, result in significant personal and societal loss, and there is no effective treatment for these disorders. Cerebellar neuropathology is common in FASD and causes aberrant cognitive and motor function. Ethanol-induced neuroinflammation is believed to contribute to neuropathological sequelae of FASD, and was previously demonstrated in the cerebellum in animal models of FASD. We now demonstrate neuroinflammation persists in the cerebellum several days following cessation of ethanol treatment in an early postnatal mouse model, with meaningful implications for timing of therapeutic intervention in FASD. We also demonstrate by Sholl analysis that ethanol decreases ramification of microglia cell processes in cells located near the Purkinje cell layer but not those near the external granule cell layer. Ethanol did not alter the expression of anti-inflammatory molecules or molecules that constitute NLRP1 and NLRP3 inflammasomes. Interestingly, ethanol decreased the expression of IL-23a (P19) and IL-12Rβ1 suggesting that ethanol may suppress IL-12 and IL-23 signaling. Fractalkine-fractalkine receptor (CX3CL1-CX3CR1) signaling is believed to suppress microglial activation and our demonstration that ethanol decreases CX3CL1 expression suggests that ethanol modulation of CX3CL1-CX3CR1 signaling may contribute to cerebellar neuroinflammation and neuropathology. We demonstrate ethanol alters the expression of specific molecules in the cerebellum understudied in FASD, but crucial for immune responses. Ethanol increases the expression of NOX-2 and NGP and decreases the expression of RAG1, NOS1, CD59a, S1PR5, PTPN22, GPR37, and Serpinb1b. These molecules represent a new horizon as potential targets for development of FASD therapy.

Indexed as

AnimalsCerebellumChemokine CX3CL1CytokinesFemaleFetal Alcohol Spectrum DisordersGene ExpressionInflammasomesMiceMice, Inbred C57BLMicrogliaNeuroinflammatory DiseasesPregnancyChemokine CX3CL1CytokinesInflammasomesFASDfractalkinemicroglianeuroinflammationRRID:AB_839504RRID:IMSR_JAX:000664RRID:SCR_016788RRID:SCR_018042RRID:SCR_018064RRID:SCR_018453

Identifiers

PMID33533128
PMCPMC8326304
OpenAlexW3126797718

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.